10x Genomics $TXG Shares Newly Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of 10x Genomics (NASDAQ:TXG) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 49,696 shares of the company’s stock, valued at approximately $4,491,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TXG. Profund Advisors LLC bought a new stake in shares of 10x Genomics in the 3rd quarter worth approximately $209,000. MGO One Seven LLC bought a new position in shares of 10x Genomics during the 3rd quarter valued at $307,000. State of Wyoming raised its position in 10x Genomics by 27.6% in the 3rd quarter. State of Wyoming now owns 7,258 shares of the company’s stock worth $656,000 after purchasing an additional 1,571 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in 10x Genomics by 17.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 21,934 shares of the company’s stock worth $1,975,000 after purchasing an additional 3,333 shares during the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new stake in 10x Genomics during the third quarter valued at about $304,000. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on TXG. Canaccord Genuity Group lifted their price objective on 10x Genomics from $60.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, October 12th. Royal Bank Of Canada started coverage on shares of 10x Genomics in a report on Tuesday, September 1st. They issued a “sector perform” rating and a $70.00 target price on the stock. Barclays lifted their target price on shares of 10x Genomics from $52.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Piper Sandler increased their price target on shares of 10x Genomics from $47.00 to $80.00 and gave the company a “neutral” rating in a research report on Monday, September 28th. Finally, Leerink Partners raised their price target on shares of 10x Genomics from $40.00 to $90.00 and gave the stock a “market perform” rating in a report on Tuesday, September 29th. Five research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, 10x Genomics presently has a consensus rating of “Hold” and an average target price of $68.07.

Trending Headlines about 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: 10x Genomics reported a Q3 loss of $0.15 per share, narrower than analysts’ expectations, while revenue of $150.7 million topped estimates. The company also raised its 2026 revenue outlook to $625 million–$635 million, above the roughly $620 million consensus. Q3 results
• Positive Sentiment: The company launched Sentira Single Cell, an AI-powered tool intended to simplify cell-data analysis. The product could support research adoption and create recurring revenue opportunities. Sentira launch
• Neutral Sentiment: Citigroup raised its price target from $50 to $60 but kept a neutral rating, suggesting limited upside at the cited share price. Citi target update
• Negative Sentiment: UBS cut its target from $90 to $61 and maintained a neutral rating. Meanwhile, Q3 revenue grew just 1.1% year over year and the company remains loss-making; management also cited production constraints and margin pressure, tempering optimism around stronger Atera demand. UBS target update Q3 call highlights

Insider Activity at 10x Genomics

In other 10x Genomics news, CEO Serge Saxonov sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $81.22, for a total transaction of $2,030,500.00. Following the transaction, the chief executive officer owned 1,050,249 shares in the company, valued at approximately $85,301,223.78. This represents a 2.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Adam Taich sold 46,388 shares of the stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $64.57, for a total value of $2,995,273.16. Following the completion of the transaction, the chief financial officer directly owned 316,344 shares of the company’s stock, valued at $20,426,332.08. This represents a 12.79% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 179,333 shares of company stock valued at $11,810,070 over the last three months. Corporate insiders own 8.84% of the company’s stock.

10x Genomics Stock Performance

Shares of 10x Genomics stock traded up $1.22 during midday trading on Friday, reaching $59.28. 4,522,645 shares of the company’s stock traded hands, compared to its average volume of 4,178,377. The company has a market cap of $7.72 billion, a PE ratio of -114.00 and a beta of 2.03. The stock has a 50 day moving average of $73.95 and a 200-day moving average of $41.59. 10x Genomics has a 12 month low of $13.58 and a 12 month high of $102.81.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.12. 10x Genomics had a negative net margin of 12.18% and a negative return on equity of 9.33%. The business had revenue of $150.67 million for the quarter, compared to the consensus estimate of $147.96 million. During the same period in the previous year, the firm earned ($0.22) EPS. The company’s quarterly revenue was up 1.1% compared to the same quarter last year. On average, equities analysts anticipate that 10x Genomics will post -0.77 earnings per share for the current fiscal year.

10x Genomics Company Profile

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.

The company’s product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples.